As reported by Liu et al., HDAC inhibitors have become known as promising therapeutic drugs that have demonstrated promise in early-stage clinical trials and preclinical research for laryngeal cancer [53]. This evidence concerns the gene HDAC9 and laryngeal carcinoma.